BACKGROUND: Patients with primary tumors of the head and neck have been reported to have a high rate of synchronous primary tumors of the upper aerodigestive tract. This study was performed to determine whether inclusion of the thorax in the scan volume would be diagnostically useful for positron emission tomography (PET) with [F-18] fluorodeoxy-D-glucose (FDG) in patients with primary tumors of the head and neck. METHODS: FDG PET scans from the midcranium to the diaphragm were obtained on 56 patients with a variety of head and neck tumors on initial examination before definitive therapy. PET findings in the chest were correlated with results of all other imaging studies, biopsy results, and clinical follow-up. RESULTS: In nine studies (16%), areas of increased FDG uptake in the chest were seen and were judged to be tumors. Six of these probably were false-positive results, although one of these six may have been unconfirmed true positives. Of the three confirmed true-positive studies, two were obvious from other routine studies. In only one case did the PET study reveal a significant lesion not found by means of routine evaluation, resulting in a case-finding yield of 2%. If the unconfirmed possible true-positive results are included, the case-finding yield increases to 4%. CONCLUSIONS: No compelling indication was seen for including the chest in PET studies of patients with head and neck cancer. Copyright 2000 John Wiley & Sons, Inc. Head Neck 22: 105-110, 2000.
BACKGROUND:Patients with primary tumors of the head and neck have been reported to have a high rate of synchronous primary tumors of the upper aerodigestive tract. This study was performed to determine whether inclusion of the thorax in the scan volume would be diagnostically useful for positron emission tomography (PET) with [F-18] fluorodeoxy-D-glucose (FDG) in patients with primary tumors of the head and neck. METHODS:FDG PET scans from the midcranium to the diaphragm were obtained on 56 patients with a variety of head and neck tumors on initial examination before definitive therapy. PET findings in the chest were correlated with results of all other imaging studies, biopsy results, and clinical follow-up. RESULTS: In nine studies (16%), areas of increased FDG uptake in the chest were seen and were judged to be tumors. Six of these probably were false-positive results, although one of these six may have been unconfirmed true positives. Of the three confirmed true-positive studies, two were obvious from other routine studies. In only one case did the PET study reveal a significant lesion not found by means of routine evaluation, resulting in a case-finding yield of 2%. If the unconfirmed possible true-positive results are included, the case-finding yield increases to 4%. CONCLUSIONS: No compelling indication was seen for including the chest in PET studies of patients with head and neck cancer. Copyright 2000 John Wiley & Sons, Inc. Head Neck 22: 105-110, 2000.
Authors: Maky A Hafidh; Peter D Lacy; Joe P Hughes; George Duffy; Conrad V Timon Journal: Eur Arch Otorhinolaryngol Date: 2006-05-25 Impact factor: 2.503
Authors: Hubert Vermeersch; David Loose; Hamphrey Ham; Andreas Otte; Christophe Van de Wiele Journal: Eur J Nucl Med Mol Imaging Date: 2003-10-22 Impact factor: 9.236
Authors: Jeffery B Jorgensen; Russell B Smith; Andrew Coughlin; William C Spanos; Michele M Lohr; Steven M Sperry; Oleg Militsakh; Robert P Zitsch; Bevan Yueh; Laura M Dooley; Aru Panwar; Tabitha L I Galloway; Nitin A Pagedar Journal: Otolaryngol Head Neck Surg Date: 2018-08-21 Impact factor: 3.497
Authors: Asaf Senft; Remco de Bree; Richard P Golding; Emile F I Comans; Jan-Hein T M Van Waesberghe; J Dirk Kuik; Otto S Hoekstra; C René Leemans Journal: Mol Imaging Biol Date: 2011-04 Impact factor: 3.488
Authors: Fernando García-Curdi; Yolanda Lois-Ortega; Ana Muniesa-Del Campo; Amaranta McGee-Laso; José Miguel Sebastián-Cortés; Héctor Vallés-Varela; Julio José Lambea-Sorrosal Journal: Braz J Otorhinolaryngol Date: 2019-07-06